What do analysts expect the price target to be for RH (RH)?
28 analysts have analysed RH and the average price target is 155.17 USD. This implies a price increase of 23.56% is expected in the next year compared to the current price of 125.58.
NYSE:RH • US74967X1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RH (RH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-07 | Goldman Sachs | Maintains | Sell -> Sell |
| 2026-04-02 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-02 | Barclays | Maintains | Overweight -> Overweight |
| 2026-04-02 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-04-01 | BNP Paribas | Maintains | Underperform -> Underperform |
| 2026-04-01 | Telsey Advisory Group | Maintains | Market Perform -> Market Perform |
| 2026-04-01 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-04-01 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-30 | TD Cowen | Maintains | Buy -> Buy |
| 2026-03-25 | Telsey Advisory Group | Maintains | Market Perform -> Market Perform |
| 2026-03-17 | UBS | Maintains | Neutral -> Neutral |
| 2026-03-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-20 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-19 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-15 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-15 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-12-12 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-12 | Stifel | Downgrade | Buy -> Hold |
| 2025-12-12 | Telsey Advisory Group | Maintains | Market Perform -> Market Perform |
| 2025-12-12 | Baird | Maintains | Neutral -> Neutral |
| 2025-12-12 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-10-02 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-09-12 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.029B -15.63% | 3.181B 5.01% | 3.44B 8.14% | 3.78B 9.90% | 4.104B 8.57% | 4.45B 8.43% | 4.888B 9.84% | 5.281B 8.04% | 5.706B 8.05% | 6.166B 8.06% | 6.662B 8.04% | |
| EBITDA YoY % growth | 493.56M -40.23% | 443.403M -10.16% | 532.393M 20.07% | 593.5M 11.48% | 686.86M 15.73% | 815.62M 18.75% | 1.222B 49.82% | 1.319B 7.94% | N/A | N/A | N/A | |
| EBIT YoY % growth | 374.571M -47.77% | 313.212M -16.38% | 383.893M 22.57% | 490.2M 27.69% | 564.62M 15.18% | 703.45M 24.59% | 904.21M 28.54% | 1.03B 13.91% | 1.118B 8.54% | 1.215B 8.68% | 1.319B 8.56% | |
| Operating Margin | 12.37% | 9.85% | 11.16% | 12.97% | 13.76% | 15.81% | 18.50% | 19.50% | 19.59% | 19.70% | 19.80% | |
| EPS YoY % growth | 6.44 -73.62% | 5.35 -16.93% | 6.30 17.76% | 6.59 4.63% | 10.33 56.66% | 15.91 54.09% | 34.95 119.64% | 41.52 18.80% | 48.19 16.08% | 56.10 16.41% | 65.55 16.83% |
All data in USD
| Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.96 -1,607.55% | 2.15 -26.71% | 2.90 69.84% | 2.76 80.09% | 1.91 197.23% | 4.97 131.68% | 4.89 68.46% | 3.51 27.47% |
| Revenue Q2Q % growth | 831.53M 2.16% | 976.6M 8.61% | 988.07M 11.80% | 966.54M 14.71% | 977.47M 17.55% | 1.08B 10.59% | 1.062B 7.48% | 1.05B 8.63% |
| EBITDA Q2Q % growth | 62.768M -31.14% | 166.76M -16.09% | 183.41M -12.99% | 175.47M -28.39% | 131.17M 108.98% | 246.17M 47.62% | 210.27M 14.64% | 198.64M 13.20% |
| EBIT Q2Q % growth | 9.94M -82.22% | 112.19M -12.95% | 127.27M 24.10% | 124.17M 28.61% | 80.649M 711.36% | 186.43M 66.17% | 158.67M 24.67% | 146.93M 18.33% |
All data in USD
28 analysts have analysed RH and the average price target is 155.17 USD. This implies a price increase of 23.56% is expected in the next year compared to the current price of 125.58.
RH (RH) will report earnings on 2026-06-10.
The consensus EPS estimate for the next earnings of RH (RH) is -1.96 USD and the consensus revenue estimate is 831.53M USD.
The consensus rating for RH (RH) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.